

Cambridge Cognition Holdings


COG 55p 0.0 0.0%

Market Cap
Enterprise Value
Revenue
Position in UK Edition

£9.54m
£6.22m
£5.11m
1566th

Value 28
Quality 36
Momentum 20
StockRank™ 18

Zoom 1w 1m 6m YTD 1y 3y 5y All



Momentum		
Relative Strength (%)		
1m	-9.0%	
3m	-18.7%	
1yr	-38.2%	
Volume Change (%)		
10d v 3m	-24.0%	
Price vs... (%)		
52w High	-33.5%	
50d MA	-9.02%	
200d MA	-9.00%	

Growth & Value			vs. industry	vs. market
12m Forecast Rolling				
PE Ratio (f)	n/a			
PEG Ratio (f)	n/a			
EPS Growth (f)	n/a %			
Dividend Yield (f)	n/a %			
Valuation (ttm)				
Price to Book Value	2.88			
Price to Tang. Book	3.23			
Price to Free Cashflow	n/a			
Price to Sales	1.87			
EV to EBITDA	n/a			

Margin of Safety (beta)



Screens Passed

COG doesn't qualify for our screens.
Find out why: [View Checklists](#)


Quality

Return on Capital	-67.0 %		vs. industry	vs. market
Return on Equity	-189 %			
Operating Margin	-43.4 %			

Financial Summary

Balance Sheet · Income Statement · Cashflow

Year End 31st Dec		2007	2008	2009	2010	2011	2012	TTM	2013E	2014E	CAGR / Avg
Revenue	£m	0.000	0.000	0.000	4.83	5.58	5.68	5.11	4.00	5.50	+8.5%
Operating Profit	£m	0.000	0.000	0.000	0.93	0.016	-1.45	-2.22			
Net Profit	£m	0.000	0.000	0.000	0.72	-0.17	-1.58	-2.31			
EPS Reported	p	0.000	0.000	0.000	13.8	-3.25	-31.9	-27.4			
EPS Normalised	p	0.000	0.000	0.000	13.8	-3.25	-31.9	-27.4	-15.2	-5.10	
EPS Growth	%										
PE Ratio	x						n/a	n/a	n/a	n/a	
PEG	x						n/a	n/a	n/a	n/a	
Profitability											
Operating Margin	%				19.1	0.3	-25.6	-43.4			-2.1%
ROA	%				42.3	-4.6		-63.0			
ROCE	%							-67.0			
ROE	%							-189			
Cashflow											
Op. Cashflow ps	p	0.000	0.000	0.000	10.5	10.8	-14.2	-17.8			+34.5%
Capex ps	p	0.000	0.000	0.000	0.62	0.82	1.11	0.037			
Free Cashflow ps	p	0.000	0.000	0.000	9.90	9.98	-15.3	-17.8			
Dividends											
Dividend ps	p										
Dividend Growth	%										
Dividend Yield	%										
Dividend Cover	x										
Balance Sheet											
Cash etc	£m	0.000	0.000	0.000	1.17	1.39	0.65	3.32			-26.1%
Working Capital	£m	n/a	n/a	n/a	-0.64	-0.79	-2.11	2.90			
Net Fixed Assets	£m	0.000	0.000	0.000	0.042	0.055	0.072	0.056			+31.3%
Net Debt	£m	0.000	0.000	0.000	0.97	0.65	1.39	-3.32			+19.6%
Book Value	£m	0.000	0.000	0.000	-0.25	-0.38	-1.68	3.31			
Average Shares	m	0.000	0.000	0.000	5.23	4.94	4.94	8.03			-2.8%
Book Value ps	p	0.000	0.000	0.000	-4.86	-7.60	-30.2	19.6			



Earnings Manipulation Risk




Other Ratios

Leverage (ttm)		total	ex intang
Gross Gearing	%	0.000	0.000
Net Gearing	%	-100.4	-112.3
Cash / Assets	%	67.1	
Liquidity (ttm)		Efficiency (ttm)	
Curr. Ratio	2.77	Asset Turnover	1.39
Quick Ratio	2.71	Rec's Turnover	4.38
Interest Cov.	-23.3	Stock Turnover	9.75

Recent History

Latest interim period (ended 30th Jun '13) vs. prior year		
Sales Growth	-22.2 %	
EPS Growth	n/a %	
3yr Compound Annual Growth Rate		
Sales Growth	n/a %	
EPS Growth	n/a %	
DPS Growth	n/a %	

Graphical History Current Fiscal Year 2013




Broker Forecasts

31st Dec 2013

31st Dec 2014

Broker Consensus Trend

1 Brokers



Price Target: 100.0 (+77.01% above Price)	Net Profit	EPS	DPS	Net Profit	EPS	DPS
Est. Long Term Growth Rate: n/a	(£)	(p)	(p)	(£)	(p)	(p)
Consensus Estimate	-	-15.2	-	-	-5.10	-
1m Change	-	-	-	-	-	-
3m Change	-	-	-	-	-	-



Profile Summary

[Home Page](#) · [News Releases](#) · [Investor Relations](#) · [Executives](#) · [Products/Services](#)



Cambridge Cognition Holdings plc is a holding company. The Company operates through its wholly owned subsidiary, Cambridge Cognition Limited (CCL). It develops and commercializes computerized neuropsychological tests for sale worldwide, principally in the United Kingdom, the United States and Europe. CCL has two products, CANTABelect and CANTABeclipse. The Company's third product, CANTABmobile targets mainstream primary healthcare markets, in particular to enable the early detection of dementia. CANTAB (being the software deployed in its commercial offering) is a suite of 25 computerized cognitive tests which are all delivered on touchscreens. CANTABeclipse is a cognitive test product designed for use by researchers working in a non-regulated environment, typically in academia. CANTABelect is a software for regulated clinical trials. The Company's technologies are used by pharmaceutical companies in their clinical trials to characterize the cognitive effects of potential new medicines.

Directors: [Jane Worlock](#) (CHM), [Nick Kerton](#) (CEO), [Nicholas Walters](#) (CFO) 55, [Andrew Blackwell](#) (CSO), [Michael Lewis](#) (NEC), [Eric Dodd](#) (NED) 44,

No. of Employees: 53

No. of Shareholders: 0

Last Annual December 31st, 2012
Last Interim June 30th, 2013
Shares in Issue 16,885,105
ISIN GB00B8DV9647

Sector [Healthcare](#)
Industry [Healthcare Equipment & Supplies](#)
Index [FTSE Aim All Share](#),
Exchange London Stock Exchange (AIM)
Eligible for an ISA? a SIPP?



Address [Tunbridge Court, Tunbridge Lane](#)
[Bottisham, CAMBRIDGE, CB25 9TU,](#)
[United Kingdom](#)
Web <http://www.cambridgecognition.com>
Phone +
Contact ()
Auditors Deloitte LLP

COG Quote

COG Share Price
 GBP
55p
 Traded 11:42am · Minimum 15 min delayed · NMS: 2.00k

Day's Change
0.0 **0.0%**


Volume
 0
Avg Vol (3m)
 2,876

Bid - Ask
 52.0 - 61.0
Open - Close
 56.5 - 56.5

Low - High
 0.0 - 0.0
12m Range
 0.0 - 0.0

Spread
 1,636bps
Beta
 0.00

COG Share Price Performance



Latest COG News Announcements (delayed)

[More »](#)

5th Jun [?1.6m phase III cognitive safety trial](#)
 3rd Jun [Launch of first two products on new platform](#)
 28th May [Cantab Mobile rolled out in NE Lincolnshire CCG](#)
 8th May [Result of AGM](#)
 8th May [AGM Statement](#)
 10th Apr [Posting of Annual Report & Notice of AGM](#)

Upcoming COG Events

No upcoming events.

Industry Peer Group

- Sphere Medical Hol...**
Compare vs COG
- Deltex Medical**
Compare vs COG
- Electrical Geodesi...**
Compare vs COG
- Lidco**
Compare vs COG
- Lifeline Scientifi...**
Compare vs COG
- Lifeline Scientifi...**
Compare vs COG
- Netscientific**
Compare vs COG
- Avacta**
Compare vs COG

[Healthcare](#)

[Healthcare Equipment & Supplies](#)

Use of our data service is subject to express Terms of Service. Please see our full site disclaimer for more details. In particular, it is very important to do your own research (DYOR) and seek professional advice before making any investment based on your own personal circumstances. Please note that the information, data and analysis contained within this stock report: (a) include the proprietary information of Stockopedia's third party licensors and Stockopedia; (b) should not be copied or redistributed except as specifically authorised; and (c) are not warranted to be complete, accurate or timely. You should independently research and verify any information that you find in this report. Stockopedia will not be liable in respect of any loss, trading or otherwise, that you may suffer arising out of such information or any reliance you may place upon it. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up. © Stockopedia 2014.